In this issue:
Ofatumumab vs rituximab in R/R DLBCL
30-month CR as a surrogate endpoint in FL
Androgens improve survival in elderly AML
High frequency and poor outcome of adult Ph+ ALL
Brain imaging to detect CNS lymphoma relapse
Venetoclax + rituximab in R/R CLL
iPET-directed treatment intensification in DLBCL
Standardised flow cytometry for MRD measurements in B-cell ALL
Subsequent cancers in lymphoma survivors
Bendamustine-replacing BCNU conditioning in lymphoma
Please login below to download this issue (PDF)